Prelude Capital Management, LLC Intra Cellular Therapies, Inc. Transaction History

Prelude Capital Management, LLC

$1.57 Billion
Q3 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$64.37 - $75.65 $624,389 - $733,805	-9,700 Reduced 67.36%	4,700 $325,000
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $259,672 - $412,440	5,600 Added 63.64%	14,400 $1.03 Million
Q3 2023 Nov 14, 2023	BUY	$52.09 - $64.1 $2,552 - $3,140	49 Added 0.56%	8,800 $458,000
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $5,193 - $6,311	95 Added 1.1%	8,751 $554,000
Q1 2023 May 15, 2023	BUY	$43.8 - $56.99 $1,138 - $1,481	26 Added 0.3%	8,656 $468,000
Q4 2022 Feb 14, 2023	SELL	$44.07 - $54.45 $25,869 - $31,962	-587 Reduced 6.37%	8,630 $456,000
Q3 2022 Nov 14, 2022	SELL	$42.7 - $59.99 $81,428 - $114,400	-1,907 Reduced 17.14%	9,217 $429,000
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $48,031 - $73,319	1,117 Added 11.16%	11,124 $635,000
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $7,399 - $11,859	-191 Reduced 1.87%	10,007 $612,000
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $133,830 - $203,102	-3,802 Reduced 27.16%	10,198 $534,000
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $86,160 - $127,470	3,000 Added 27.27%	14,000 $522,000
Q2 2021 Aug 16, 2021	BUY	$29.3 - $44.5 $166,482 - $252,849	5,682 Added 106.84%	11,000 $449,000
Q1 2019 May 15, 2019	BUY	$10.9 - $14.09 $53,290 - $68,886	4,889 Added 1139.63%	5,318 $65,000
Q4 2018 Feb 14, 2019	SELL	$10.36 - $20.96 $195,296 - $395,116	-18,851 Reduced 97.77%	429 $5,000
Q3 2018 Nov 14, 2018	BUY	$17.77 - $22.9 $3,216 - $4,144	181 Added 0.95%	19,280 $418,000
Q2 2018 Aug 14, 2018	BUY	$17.33 - $23.4 $7,867 - $10,623	454 Added 2.43%	19,099 $337,000
Q1 2018 May 15, 2018	BUY	$15.16 - $25.49 $264,845 - $445,310	17,470 Added 1486.81%	18,645 $392,000
Q4 2017 Feb 14, 2018	SELL	$14.27 - $16.79 $8,376 - $9,855	-587 Reduced 33.31%	1,175 $17,000
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $18,976 - $38,940	1,762	1,762 $28,000

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

Vanguard Group Inc Valley Forge, PA

9.63M
Shares

$800 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.32M
Shares

$525 Million
0.01% of portfolio
Jpmorgan Chase & CO New York, NY

5.29M
Shares

$439 Million
0.03% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

3.85M
Shares

$320 Million
1.4% of portfolio
Avoro Capital Advisors LLC New York, NY

3.05M
Shares

$253 Million
3.36% of portfolio

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.85B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Account